Table 2 (for time-overlapping scenario 2).
site | APC1 | APC2 | naive T-test | Corrected Z-test | estimated residual variance |
---|---|---|---|---|---|
All Malignant Cancers | −0.5 | −0.5 | 0.075 | 0.052 | 6.81E-05 |
−0.5 | −0.3 | 0.840 | 0.830 | 6.84E-05 | |
−0.5 | −0.1 | 1.00 | 0.99 | 6.82E-05 | |
−0.3 | −0.3 | 0.075 | 0.058 | 6.77E-05 | |
−0.3 | −0.1 | 0.843 | 0.831 | 6.78E-05 | |
−0.3 | 0.1 | 1.00 | 1.00 | 6.74E-05 | |
−0.1 | −0.1 | 0.074 | 0.052 | 6.67E-05 | |
−0.1 | 0.1 | 0.851 | 0.831 | 6.65E-05 | |
−0.1 | 0.3 | 1.00 | 1.00 | 6.62E-05 | |
0.1 | 0.1 | 0.073 | 0.054 | 6.58E-05 | |
0.1 | 0.3 | 0.854 | 0.831 | 6.54E-05 | |
0.1 | 0.5 | 1.00 | 0.99 | 6.53E-05 | |
0.3 | 0.3 | 0.071 | 0.054 | 6.62E-05 | |
0.3 | 0.5 | 0.859 | 0.846 | 6.51E-05 | |
0.3 | 0.7 | 1.00 | 1.00 | 6.44E-05 | |
0.5 | 0.5 | 0.075 | 0.054 | 6.42E-05 | |
0.5 | 0.7 | 0.862 | 0.849 | 6.40E-05 | |
0.5 | 1.0 | 1.00 | 1.00 | 6.35E-05 | |
Prostate Cancer | −0.5 | −0.5 | 0.076 | 0.052 | 0.00061 |
−0.5 | −0.3 | 0.198 | 0.189 | 0.00061 | |
−0.5 | −0.1 | 0.540 | 0.517 | 0.00061 | |
−0.5 | 0.1 | 0.850 | 0.837 | 0.00061 | |
−0.3 | −0.3 | 0.075 | 0.050 | 0.00060 | |
−0.3 | −0.1 | 0.199 | 0.183 | 0.00059 | |
−0.3 | 0.1 | 0.544 | 0.523 | 0.00058 | |
−0.3 | 0.3 | 0.854 | 0.840 | 0.00057 | |
−0.1 | −0.1 | 0.075 | 0.058 | 0.00057 | |
−0.1 | 0.1 | 0.201 | 0.185 | 0.00057 | |
−0.1 | 0.3 | 0.545 | 0.526 | 0.00057 | |
−0.1 | 0.5 | 0.95 | 0.97 | 0.00057 | |
0.1 | 0.1 | 0.074 | 0.053 | 0.00057 | |
0.1 | 0.3 | 0.203 | 0.186 | 0.00057 | |
0.1 | 0.5 | 0.550 | 0.530 | 0.00057 | |
0.1 | 0.7 | 0.859 | 0.845 | 0.00057 | |
0.3 | 0.3 | 0.075 | 0.051 | 0.00057 | |
0.3 | 0.5 | 0.205 | 0.188 | 0.00057 | |
0.3 | 0.7 | 0.555 | 0.533 | 0.00057 | |
0.3 | 1.0 | 0.941 | 0.933 | 0.00057 | |
0.5 | 0.5 | 0.075 | 0.052 | 0.00056 | |
0.5 | 0.7 | 0.205 | 0.190 | 0.00056 | |
0.5 | 1.0 | 0.736 | 0.717 | 0.00056 |